Table 2. Leukemias diagnosed in this... | American Society of Hematology

Table 2.

Leukemias diagnosed in this study

Vector and mouse no.	Leukocyte counts (× 10⁶/mL)	Latency of manifestation (wks)	Flow cytometry	Spleen weight, mg	Copy number after 9 weeks‡	Copy number in leukemia§	Diagnosis
SF91PDsRED2
5^*	12.6	26	CD11b⁺, GR1⁺	200	14	8	MPD-like myeloid leukemia
5.1^* (secondary of 5)	250	26 + 12	CD11b⁺ c-Kit⁺	850	ND	8	Myeloid leukemia with maturation
5.2^* (secondary of 5)	430	26 + 20	CD11b⁺ c-Kit⁺	380	ND	8	Myeloid leukemia with maturation
HaMDR1
29^*	5.7	34	BM: all marker low; spleen:CD3⁺, CD4⁺, CD8⁺	170, thymus enlarged	0.8	7	Precursor T-lymphoblastic lymphoma/leukemia
31^*	3.9	16	Ter119 low, c-Kit⁺	300	3	6	Erythroid leukemia
31.2^* (secondary of 31)	10	16 + 10	Ter119 low, c-Kit⁺	580	ND	6	Erythroid leukemkia
40†	78	26	CD11b⁺, Gr1^+/-	510	20	10	Myeloid leukemia with maturation
43†	14	33	CD11b⁺, Gr1^+/-	780	7.6	ND	Myeloid leukemia with maturation
44†	1.5	33	CD11b⁺, c-Kit⁺	510	5.5	10	Myeloid leukemia without maturation
45†	NA	24	NA	Thymus/spleen enlarged	12.8	NA	(Most likely) T-cell leukemia
46†	1	32	CD11b⁺, GR1⁺	635	38.8	12	Myeloid leukemia with maturation
28.2^* (secondary of 28)	40	26 + 21	CD3⁺ recipient type	860	Mouse 28 = 0.82	0	Precursor T-lymphoblastic lymphoma/leukemia

Vector and mouse no.	Leukocyte counts (× 10⁶/mL)	Latency of manifestation (wks)	Flow cytometry	Spleen weight, mg	Copy number after 9 weeks‡	Copy number in leukemia§	Diagnosis
SF91PDsRED2
5^*	12.6	26	CD11b⁺, GR1⁺	200	14	8	MPD-like myeloid leukemia
5.1^* (secondary of 5)	250	26 + 12	CD11b⁺ c-Kit⁺	850	ND	8	Myeloid leukemia with maturation
5.2^* (secondary of 5)	430	26 + 20	CD11b⁺ c-Kit⁺	380	ND	8	Myeloid leukemia with maturation
HaMDR1
29^*	5.7	34	BM: all marker low; spleen:CD3⁺, CD4⁺, CD8⁺	170, thymus enlarged	0.8	7	Precursor T-lymphoblastic lymphoma/leukemia
31^*	3.9	16	Ter119 low, c-Kit⁺	300	3	6	Erythroid leukemia
31.2^* (secondary of 31)	10	16 + 10	Ter119 low, c-Kit⁺	580	ND	6	Erythroid leukemkia
40†	78	26	CD11b⁺, Gr1^+/-	510	20	10	Myeloid leukemia with maturation
43†	14	33	CD11b⁺, Gr1^+/-	780	7.6	ND	Myeloid leukemia with maturation
44†	1.5	33	CD11b⁺, c-Kit⁺	510	5.5	10	Myeloid leukemia without maturation
45†	NA	24	NA	Thymus/spleen enlarged	12.8	NA	(Most likely) T-cell leukemia
46†	1	32	CD11b⁺, GR1⁺	635	38.8	12	Myeloid leukemia with maturation
28.2^* (secondary of 28)	40	26 + 21	CD3⁺ recipient type	860	Mouse 28 = 0.82	0	Precursor T-lymphoblastic lymphoma/leukemia

ND indicates not determined; NA, not applicable (mouse found dead).

Bone marrow transplantation (BMT) was performed with cells that were expanded for 2 days after the first exposure to retroviral particles

BMT was performed with cells that were expanded for 10 days after the first exposure to retroviral particles

Transgene copy number was determined in peripheral blood cells by real-time PCR

Transgene copy number in leukemias was determined by Southern blot